



## Lung-RADS® Version 1.1

Assessment Categories Release date: 2019

Category Descriptor	Lung-RADS Score	Findings	Management	Risk of Malignancy	Est. Population Prevalence
<b>Incomplete</b>	<b>0</b>	Prior chest CT examination(s) being located for comparison Part or all of lungs cannot be evaluated	Additional lung cancer screening CT images and/or comparison to prior chest CT examinations is needed	n/a	1%
<b>Negative</b> No nodules and definitely benign nodules	<b>1</b>	No lung nodules Nodule(s) with specific calcifications: complete, central, popcorn, concentric rings and fat containing nodules	Continue annual screening with LDCT in 12 months	< 1%	90%
<b>Benign Appearance or Behavior</b> Nodules with a very low likelihood of becoming a clinically active cancer due to size or lack of growth	<b>2</b>	<b>Perifissural nodule(s)</b> (See Footnote 1f) < 10 mm (523.6mm <sup>3</sup> )			
		<b>Solid nodule(s):</b> < 6 mm (< 113.1 mm <sup>3</sup> ) new < 4 mm (< 33.5 mm <sup>3</sup> )			
		<b>Part solid nodule(s):</b> < 6 mm total diameter (< 113.1 mm <sup>3</sup> ) on baseline screening			
		<b>Non solid nodule(s) (GGN):</b> < 30 mm (< 14137.2 mm <sup>3</sup> ) OR ≥ 30 mm (≥ 14137.2 mm <sup>3</sup> ) and unchanged or slowly growing			
<b>Probably Benign</b> Probably benign finding(s) - short term follow up suggested; includes nodules with a low likelihood of becoming a clinically active cancer	<b>3</b>	<b>Solid nodule(s):</b> ≥ 6 to < 8 mm (≥ 113.1 to < 268.1 mm <sup>3</sup> ) at baseline OR new 4 mm to < 6 mm (33.5 to < 113.1mm <sup>3</sup> )	6 month LDCT	1-2%	5%
		<b>Part solid nodule(s)</b> ≥ 6 mm total diameter (≥ 113.1 mm <sup>3</sup> ) with solid component < 6 mm (< 113.1 mm <sup>3</sup> ) OR new < 6 mm total diameter (< 113.1 mm <sup>3</sup> )			
		<b>Non solid nodule(s)</b> (GGN) ≥ 30 mm (≥ 14137.2 mm <sup>3</sup> ) on baseline CT or new			
<b>Suspicious</b> Findings for which additional diagnostic testing is recommended	<b>4A</b>	<b>Solid nodule(s):</b> ≥ 8 to < 15 mm (≥ 268.1 to < 1767.1 mm <sup>3</sup> ) at baseline OR growing < 8 mm (< 268.1 mm <sup>3</sup> ) OR new 6 to < 8 mm (113.1 to < 268.1 mm <sup>3</sup> )	3 month LDCT; PET/CT may be used when there is a ≥ 8 mm (≥ 268.1 mm <sup>3</sup> ) solid component	5-15%	2%
		<b>Part solid nodule(s):</b> ≥ 6 mm (≥ 113.1 mm <sup>3</sup> ) with solid component ≥ 6 mm to < 8 mm (≥ 113.1 to < 268.1 mm <sup>3</sup> ) OR with a new or growing < 4 mm (< 33.5 mm <sup>3</sup> ) solid component			
		<b>Endobronchial nodule</b>			
<b>Very Suspicious</b> Findings for which additional diagnostic testing and/or tissue sampling is recommended	<b>4B</b>	<b>Solid nodule(s)</b> ≥ 15 mm (≥ 1767.1 mm <sup>3</sup> ) OR new or growing, and ≥ 8 mm (≥ 268.1 mm <sup>3</sup> )	Chest CT with or without contrast, PET/CT and/or tissue sampling depending on the "probability of malignancy and comorbidities. PET/CT may be used when there is a ≥ 8 mm (≥ 268.1 mm <sup>3</sup> ) solid component. For new large nodules that develop on an annual repeat screening CT, a 1 month LDCT may be recommended to address potentially infectious or inflammatory conditions	> 15%	2%
		<b>Part solid nodule(s) with:</b> a solid component ≥ 8 mm (≥ 268.1 mm <sup>3</sup> ) OR a new or growing ≥ 4 mm (≥ 33.5 mm <sup>3</sup> ) solid component			
<b>Other</b> Clinically Significant or Potentially Clinically Significant Findings (non lung cancer)	<b>S</b>	<b>Modifier - may add on to category 0-4 coding</b>	As appropriate to the specific finding	n/a	10%